The present disclosure relates to ABCA1 inducer compounds for use in treating kidney disorders, and in particular, chronic kidney diseases, glomerular diseases or proteinuric kidney diseases such as Alport syndrome, focal segmental glomerulosclerosis, and diabetic kidney disease.本發明係關於ABCA1誘導劑化合物,用於治療腎臟病,且特別是慢性腎病、腎小球疾病或蛋白尿腎病,諸如奧爾波特症候群(Alport syndrome)、局部區段性腎小球硬化及糖尿病性腎病。